Transfection of primary CLL cells from U-cases with the specific antagomir targeting miR-26b-5p results in up-regulation of the cyclin-dependent kinase inhibitor p21−Cip1 and down-modulation of the oncogene c-Myc (p = 0.015 and p = 0.031, respectively, Wilcoxon signed-rank test, n = 7, Figure 4C,D). The gene discussed is CDKN3; the disease is B-cell chronic lymphocytic leukemia.